费森尤斯Fresenius（FMS）2025年第四季度及全年财报电话会议纪要PPT「NYSE」（英文版）（57页）.pdf

1、#FutureFresenius:REJUVENATE in Action delivering accelerated performance for long-term value creationFull year and Q4 2025 resultsConference call and webcast for investors and analystsBad Homburg,25 February 2026Strategy and Business UpdateFinancials#FutureFreseniusAppendixSafe Harbor StatementThis

2、presentation contains forward-looking statements that are subject to various risks and uncertainties.Future results could differ materially from those described in these forward-looking statements due to certain factors,e.g.changes in business,economic and competitive conditions,regulatory reforms,r

3、esults of clinical trials,foreign exchange rate fluctuations,uncertainties in litigation or investigative proceedings,the availability of financing and unforeseen impacts of international conflicts.Fresenius does not undertake any responsibility to update the forward-looking statements contained in

4、this presentation.Q4/25 Earnings Call,25 February 2026 Fresenius SE&Co.KGaA Investor Relations2ccat constant currencyCore Net incomeNet income excluding Fresenius Medical CareCore EPSEarnings per share excluding Fresenius Medical CareGlossaryStrategy and Business UpdateFinancials#FutureFreseniusAppe

5、ndix01Strategy and Business Update02Financials03#FutureFresenius04Appendix01Strategy and Business UpdateStrategy and Business UpdateFinancials#FutureFreseniusAppendixAnother year of strong deliveryQ4/25 Earnings Call,25 February 2026 Fresenius SE&Co.KGaA Investor RelationsBefore special items|P&L gr

6、owth rates adjusted for ARG hyperinflation|1Excl.FMC;at average exchange rates for both net debt and EBITDA;before special items;pro forma closed acquisitions/divestitures,including lease liabilities,including Fresenius Medical Care dividend;Net debt adjusted for valuation effect of exchangeable bon